Cargando…
A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder
RATIONALE: Treatment of attention-deficit/hyperactivity disorder (ADHD) has for many years relied on psychostimulants, particularly various formulations of amphetamines and methylphenidate. These are central nervous system stimulants and are scheduled because of their abuse potential. Atomoxetine (a...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579642/ https://www.ncbi.nlm.nih.gov/pubmed/23397050 http://dx.doi.org/10.1007/s00213-013-2986-z |
_version_ | 1782260139071373312 |
---|---|
author | Upadhyaya, Himanshu P. Desaiah, Durisala Schuh, Kory J. Bymaster, Frank P. Kallman, Mary J. Clarke, David O. Durell, Todd M. Trzepacz, Paula T. Calligaro, David O. Nisenbaum, Eric S. Emmerson, Paul J. Schuh, Leslie M. Bickel, Warren K. Allen, Albert J. |
author_facet | Upadhyaya, Himanshu P. Desaiah, Durisala Schuh, Kory J. Bymaster, Frank P. Kallman, Mary J. Clarke, David O. Durell, Todd M. Trzepacz, Paula T. Calligaro, David O. Nisenbaum, Eric S. Emmerson, Paul J. Schuh, Leslie M. Bickel, Warren K. Allen, Albert J. |
author_sort | Upadhyaya, Himanshu P. |
collection | PubMed |
description | RATIONALE: Treatment of attention-deficit/hyperactivity disorder (ADHD) has for many years relied on psychostimulants, particularly various formulations of amphetamines and methylphenidate. These are central nervous system stimulants and are scheduled because of their abuse potential. Atomoxetine (atomoxetine hydrochloride; Strattera®) was approved in 2002 for treatment of ADHD, and was the first nonstimulant medication approved for this disorder. It was classified as an unscheduled medication indicating a low potential for abuse. However, the abuse potential of atomoxetine has not been reviewed. OBJECTIVES: In this article, we review the evidence regarding abuse potential of atomoxetine, a selective inhibitor of the presynaptic norepinephrine transporter, which is unscheduled/unrestricted in all countries where it is approved. METHODS: Results from receptor binding, in vitro electrophysiology, in vivo microdialysis, preclinical behavioral, and human laboratory studies have been reviewed. RESULTS: Atomoxetine has no appreciable affinity for, or action at, central receptors through which drugs of abuse typically act, i.e., dopamine transporters, GABA(A) receptors, and opioid μ receptors. In behavioral experiments in rodents, atomoxetine does not increase locomotor activity, and in drug discrimination studies, its profile is similar to that of drugs without abuse potential. Atomoxetine does not serve as a reinforcer in monkey self-administration studies, and human laboratory studies suggest that atomoxetine does not induce subjective effects indicative of abuse. CONCLUSION: Neurochemical, preclinical, and early clinical studies predicted and supported a lack of abuse potential of atomoxetine, which is consistent with the clinical trial and postmarketing spontaneous event data in the past 10 years. |
format | Online Article Text |
id | pubmed-3579642 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Springer-Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-35796422013-02-26 A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder Upadhyaya, Himanshu P. Desaiah, Durisala Schuh, Kory J. Bymaster, Frank P. Kallman, Mary J. Clarke, David O. Durell, Todd M. Trzepacz, Paula T. Calligaro, David O. Nisenbaum, Eric S. Emmerson, Paul J. Schuh, Leslie M. Bickel, Warren K. Allen, Albert J. Psychopharmacology (Berl) Review RATIONALE: Treatment of attention-deficit/hyperactivity disorder (ADHD) has for many years relied on psychostimulants, particularly various formulations of amphetamines and methylphenidate. These are central nervous system stimulants and are scheduled because of their abuse potential. Atomoxetine (atomoxetine hydrochloride; Strattera®) was approved in 2002 for treatment of ADHD, and was the first nonstimulant medication approved for this disorder. It was classified as an unscheduled medication indicating a low potential for abuse. However, the abuse potential of atomoxetine has not been reviewed. OBJECTIVES: In this article, we review the evidence regarding abuse potential of atomoxetine, a selective inhibitor of the presynaptic norepinephrine transporter, which is unscheduled/unrestricted in all countries where it is approved. METHODS: Results from receptor binding, in vitro electrophysiology, in vivo microdialysis, preclinical behavioral, and human laboratory studies have been reviewed. RESULTS: Atomoxetine has no appreciable affinity for, or action at, central receptors through which drugs of abuse typically act, i.e., dopamine transporters, GABA(A) receptors, and opioid μ receptors. In behavioral experiments in rodents, atomoxetine does not increase locomotor activity, and in drug discrimination studies, its profile is similar to that of drugs without abuse potential. Atomoxetine does not serve as a reinforcer in monkey self-administration studies, and human laboratory studies suggest that atomoxetine does not induce subjective effects indicative of abuse. CONCLUSION: Neurochemical, preclinical, and early clinical studies predicted and supported a lack of abuse potential of atomoxetine, which is consistent with the clinical trial and postmarketing spontaneous event data in the past 10 years. Springer-Verlag 2013-02-09 2013 /pmc/articles/PMC3579642/ /pubmed/23397050 http://dx.doi.org/10.1007/s00213-013-2986-z Text en © The Author(s) 2013 https://creativecommons.org/licenses/by-nc/2.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Review Upadhyaya, Himanshu P. Desaiah, Durisala Schuh, Kory J. Bymaster, Frank P. Kallman, Mary J. Clarke, David O. Durell, Todd M. Trzepacz, Paula T. Calligaro, David O. Nisenbaum, Eric S. Emmerson, Paul J. Schuh, Leslie M. Bickel, Warren K. Allen, Albert J. A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder |
title | A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder |
title_full | A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder |
title_fullStr | A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder |
title_full_unstemmed | A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder |
title_short | A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder |
title_sort | review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579642/ https://www.ncbi.nlm.nih.gov/pubmed/23397050 http://dx.doi.org/10.1007/s00213-013-2986-z |
work_keys_str_mv | AT upadhyayahimanshup areviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder AT desaiahdurisala areviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder AT schuhkoryj areviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder AT bymasterfrankp areviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder AT kallmanmaryj areviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder AT clarkedavido areviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder AT durelltoddm areviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder AT trzepaczpaulat areviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder AT calligarodavido areviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder AT nisenbaumerics areviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder AT emmersonpaulj areviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder AT schuhlesliem areviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder AT bickelwarrenk areviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder AT allenalbertj areviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder AT upadhyayahimanshup reviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder AT desaiahdurisala reviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder AT schuhkoryj reviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder AT bymasterfrankp reviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder AT kallmanmaryj reviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder AT clarkedavido reviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder AT durelltoddm reviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder AT trzepaczpaulat reviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder AT calligarodavido reviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder AT nisenbaumerics reviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder AT emmersonpaulj reviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder AT schuhlesliem reviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder AT bickelwarrenk reviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder AT allenalbertj reviewoftheabusepotentialassessmentofatomoxetineanonstimulantmedicationforattentiondeficithyperactivitydisorder |